nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.03.2008

Immune cells as mediators of solid tumor metastasis

verfasst von: David G. DeNardo, Magnus Johansson, Lisa M. Coussens

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Outgrowths of disseminated metastases remain the primary cause of mortality in cancer patients; however, molecular and cellular mechanisms regulating metastatic spread remain largely elusive. Recent insights into these mechanisms have refined the seed and soil hypothesis and it is now recognized that metastasis of solid tumors requires collaborative interactions between malignant cells and a diverse assortment of “activated” stromal cells at both primary and secondary tumor locations. Specifically, persistent pro-tumor immune responses (inflammation), now generally accepted as potentiating primary tumor development, are also being recognized as mediators of cancer metastasis. Thus, novel anti-cancer therapeutic strategies targeting molecular and/or cellular mechanisms regulating these collaborative interactions may provide efficacious relief for metastatic disease. This review focuses on recent literature revealing new mechanisms whereby immune cells regulate metastatic progression, with a primary focus on breast cancer.

Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007). Cancer statistics. CA A Cancer Journal for Clinicians, 57, 43–66 2007.PubMedCrossRef

Paget, S. (1889). The distribution of secondary growths in cancer of the breast. Lancet, 1, 571–573.CrossRef

Karin, M., & Greten, F. R. (2005). NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nature Reviews. Immunology, 5, 749–759.PubMedCrossRef

Coussens, L. M., & Werb, Z. (2001). Inflammatory cells and cancer: Think different!. Journal of Experimental Medicine, 193, F23–F26.PubMedCrossRef

Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature, 420, 860–867.PubMedCrossRef

Balkwill, F., & Coussens, L. M. (2004). Cancer: An inflammatory link. Nature, 431, 405–406.PubMedCrossRef

Balkwill, F., & Mantovani, A. (2001). Inflammation and cancer: Back to Virchow? Lancet, 357, 539–545.PubMedCrossRef

Balkwill, F., Charles, K. A., & Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 7, 211–217.PubMedCrossRef

de Visser, K. E., Eichten, A., & Coussens, L. M. (2006). Paradoxical roles of the immune system during cancer development. Nature Reviews Cancer, 6, 24–37.PubMedCrossRef

10.

Fidler, I. J. (2003). The pathogenesis of cancer metastasis: The ‘seed and soil’ hypothesis revisited. Nature Reviews. Cancer, 3, 453–458.PubMedCrossRef

11.

Chambers, A. F., Naumov, G. N., Varghese, H. J., Nadkarni, K. V., MacDonald, I. C., & Groom, A. C. (2001). Critical steps in hematogenous metastasis: An overview. Surgical Oncology Clinics of North America, 10, 243–255 vii.PubMed

12.

Folkman, J. (1992). The role of angiogenesis in tumor growth. Seminars in Cancer Biology, 3, 65–71.PubMed

13.

Woodhouse, E. C., Chuaqui, R. F., & Liotta, L. A. (1997). General mechanisms of metastasis. Cancer, 80, 1529–1537.PubMedCrossRef

14.

Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57–70.PubMedCrossRef

15.

Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature, 410, 50–56.PubMedCrossRef

16.

Wilson, J., & Balkwill, F. (2002). The role of cytokines in the epithelial cancer microenvironment. Seminars in Cancer Biology, 12, 113–120.PubMedCrossRef

17.

Borsig, L., Wong, R., Hynes, R. O., Varki, N. M., & Varki, A. (2002). Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proceedings of the National Academy of Sciences of the United States of America, 99, 2193–2198.PubMedCrossRef

18.

Laakkonen, P., Porkka, K., Hoffman, J. A., & Ruoslahti, E. (2002). A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nature Medicine, 8, 751–755.

19.

Karin, M., Lawrence, T., & Nizet, V. (2006). Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer. Cell, 124, 823–835.PubMedCrossRef

20.

Wu, J., & Lanier, L. L. (2003). Natural killer cells and cancer. Advances in Cancer Research, 90, 127–156.PubMed

21.

Theoharides, T. C., & Conti, P. (2004). Mast cells: The Jekyll and Hyde of tumor growth. Trends in Immunology, 25, 235–241.PubMedCrossRef

22.

Condeelis, J., & Pollard, J. W. (2006). Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell, 124, 263–266.PubMedCrossRef

23.

Mantovani, A., Allavena, P., & Sica, A. (2004). Tumour-associated macrophages as a prototypic type II polarised phagocyte population: Role in tumour progression. European Journal of Cancer, 40, 1660–1667.PubMedCrossRef

24.

Goswami, S., Sahai, E., Wyckoff, J. B., Cammer, M., Cox, D., Pixley, F. J., et al. (2005). Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Research, 65, 5278–5283.PubMedCrossRef

25.

Wyckoff, J., Wang, W., Lin, E. Y., Wang, Y., Pixley, F., Stanley, E. R., et al. (2004). A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Research, 64, 7022–7029.PubMedCrossRef

26.

Bergers, G., & Benjamin, L. E. (2003). Angiogenesis: Tumorigenesis and the angiogenic switch. Nature Reviews. Cancer, 3, 401–410.PubMedCrossRef

27.

Wyckoff, J. B., Wang, Y., Lin, E. Y., Li, J. F., Goswami, S., Stanley, E. R., et al. (2007). Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Research, 67, 2649–2656.PubMedCrossRef

28.

Lee, T. H., Seng, S., Sekine, M., Hinton, C., Fu, Y., Avraham, H. K., et al. (2007). Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Medicine, 4, e186.PubMedCrossRef

29.

Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., et al. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology, 2, 737–744.PubMedCrossRef

30.

Coussens, L. M., Raymond, W. W., Bergers, G., Laig-Webster, M., Behrendtsen, O., Werb, Z., et al. (1999). Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes & Development, 13, 1382–1397.

31.

Lin, E. Y., & Pollard, J. W. (2007). Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Research, 67, 5064–5066.PubMedCrossRef

32.

Robinson-Smith, T. M., Isaacsohn, I., Mercer, C. A., Zhou, M., Van Rooijen, N., Husseinzadeh, N., et al. (2007). Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Research, 67, 5708–5716.PubMedCrossRef

33.

Guy, C. T., Cardiff, R. D., & Muller, W. J. (1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Molecular and Cellular Biology, 12, 954–961.PubMed

34.

Lin, E. Y., Gouon-Evans, V., Nguyen, A. V., & Pollard, J. W. (2002). The macrophage growth factor CSF-1 in mammary gland development and tumor progression. Journal of Mammary Gland Biology and Neoplasia, 7, 147–162.PubMedCrossRef

35.

Lin, E. Y., Li, J. F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D. A., et al. (2006). Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Research, 66, 11238–11246.PubMedCrossRef

36.

O’Sullivan, C., & Lewis, C. E. (1994). Tumour-associated leucocytes: Friends or foes in breast carcinoma. Journal of Pathology, 172, 229–235.PubMedCrossRef

37.

Leek, R. D., & Harris, A. L. (2002). Tumor-associated macrophages in breast cancer. Journal of Mammary Gland Biology and Neoplasia, 7, 177–189.PubMedCrossRef

38.

Bolat, F., Kayaselcuk, F., Nursal, T. Z., Yagmurdur, M. C., Bal, N., & Demirhan, B. (2006). Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: Correlations with prognostic parameters. Journal of Experimental & Clinical Cancer Research, 25, 365–372.

39.

Tsutsui, S., Yasuda, K., Suzuki, K., Tahara, K., Higashi, H., & Era, S. (2005). Macrophage infiltration and its prognostic implications in breast cancer: The relationship with VEGF expression and microvessel density. Oncology Reports, 14, 425–431.PubMed

40.

Ohno, S., Ohno, Y., Suzuki, N., Kamei, T., Koike, K., Inagawa, H., et al. (2004). Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Research, 24, 3335–3342.PubMed

41.

Oosterling, S. J., van der Bij, G. J., Meijer, G. A., Tuk, C. W., van Garderen, E., van Rooijen, N., et al. (2005). Macrophages direct tumour histology and clinical outcome in a colon cancer model. Journal of Pathology, 207, 147–155.PubMedCrossRef

42.

Coussens, L. M., Tinkle, C. L., Hanahan, D., & Werb, Z. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103, 481–490.PubMedCrossRef

43.

Ribatti, D., Crivellato, E., Roccaro, A. M., Ria, R., & Vacca, A. (2004). Mast cell contribution to angiogenesis related to tumour progression. Clinical & Experimental Allergy, 34, 1660–1664.CrossRef

44.

Ribatti, D., Vacca, A., Nico, B., Crivellato, E., Roncali, L., & Dammacco, F. (2001). The role of mast cells in tumour angiogenesis. British Journal of Haematology, 115, 514–521.PubMedCrossRef

45.

Benelli, R., Albini, A., & Noonan, D. (2003). Neutrophils and angiogenesis: Potential initiators of the angiogenic cascade. Chemical Immunology and Allergy, 83, 167–181.PubMed

46.

Sinha, P., Clements, V. K., Fulton, A. M., & Ostrand-Rosenberg, S. (2007). Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Research, 67, 4507–4513.PubMedCrossRef

47.

De Palma, M., Venneri, M. A., Galli, R., Sergi Sergi, L., Politi, L. S., Sampaolesi, M., et al. (2005). Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell, 8, 211–226.PubMedCrossRef

48.

Bunt, S. K., Sinha, P., Clements, V. K., Leips, J., & Ostrand-Rosenberg, S. (2006). Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. Journal of Immunology, 176, 284–290.

49.

Egeblad, M., & Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nature Reviews. Cancer, 2, 161–174.PubMedCrossRef

50.

Mueller, M. M., & Fusenig, N. E. (2004). Friends or foes—Bipolar effects of the tumour stroma in cancer. Nature Reviews. Cancer, 4, 839–849.PubMedCrossRef

51.

Joyce, J. A., & Hanahan, D. (2004). Multiple roles for cysteine cathepsins in cancer. Cell Cycle, 3, 1516–1619.PubMed

52.

Giannelli, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson, W. G., & Quaranta, V. (1997). Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science, 277, 225–228.PubMedCrossRef

53.

Pirila, E., Ramamurthy, N. S., Sorsa, T., Salo, T., Hietanen, J., & Maisi, P. (2003). Gelatinase A (MMP-2), collagenase-2 (MMP-8), and laminin-5 gamma2-chain expression in murine inflammatory bowel disease (ulcerative colitis). Digestive Diseases and Sciences, 48, 93–98.PubMedCrossRef

54.

Kalluri, R. (2003). Basement membranes: Structure, assembly and role in tumour angiogenesis. Nature Reviews. Cancer, 3, 422–433.PubMedCrossRef

55.

van Kempen, L. C., de Visser, K. E., & Coussens, L. M. (2006). Inflammation, proteases and cancer. European Journal of Cancer, 42, 728–734.PubMedCrossRef

56.

Cheng, K., Xie, G., & Raufman, J. P. (2007). Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line. Biochemical Pharmacology, 73, 1001–1012.PubMedCrossRef

57.

Wang, F., Sloss, C., Zhang, X., Lee, S. W., & Cusack, J. C. (2007). Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells. Cancer Research, 67, 8486–8493.PubMedCrossRef

58.

Gocheva, V., Zeng, W., Ke, D., Klimstra, D., Reinheckel, T., Peters, C., et al. (2006). Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes & Development, 20, 543–556.CrossRef

59.

Vasiljeva, O., Papazoglou, A., Kruger, A., Brodoefel, H., Korovin, M., Deussing, J., et al. (2006). Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Research, 66, 5242–5250.PubMedCrossRef

60.

Lin, E. Y., Jones, J. G., Li, P., Zhu, L., Whitney, K. D., Muller, W. J., et al. (2003). Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. American Journal of Pathology, 163, 2113–2126.PubMed

61.

Hagemann, T., Wilson, J., Kulbe, H., Li, N. F., Leinster, D. A., Charles, K., et al. (2005). Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. Journal of Immunology, 175, 1197–1205.

62.

Scott, K. A., Arnott, C. H., Robinson, S. C., Moore, R. J., Thompson, R. G., Marshall, J. F., et al. (2004). TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration? Oncogene, 23, 6954–6966.PubMedCrossRef

63.

Szlosarek, P. W., Grimshaw, M. J., Kulbe, H., Wilson, J. L., Wilbanks, G. D., Burke, F., et al. (2006). Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Molecular Cancer Therapeutics, 5, 382–390.PubMedCrossRef

64.

Szlosarek, P., Charles, K. A., & Balkwill, F. R. (2006). Tumour necrosis factor-alpha as a tumour promoter. European Journal of Cancer, 42, 745–750.PubMedCrossRef

65.

Luo, J. L., Tan, W., Ricono, J. M., Korchynskyi, O., Zhang, M., Gonias, S. L., et al. (2007). Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature, 446, 690–694.PubMedCrossRef

66.

Abraham, S., Zhang, W., Greenberg, N., & Zhang, M. (2003). Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells. Journal of Urology, 169, 1157–1161.PubMedCrossRef

67.

Sager, R., Sheng, S., Pemberton, P., & Hendrix, M. J. (1997). Maspin. A tumor suppressing serpin. Advances in Experimental Medicine and Biology, 425, 77–88.PubMed

68.

Chen, E. I., & Yates, J. R. (2006). Maspin and tumor metastasis. IUMB Life, 58, 25–29.CrossRef

69.

Jones, D. H., Nakashima, T., Sanchez, O. H., Kozieradzki, I., Komarova, S. V., Sarosi, I., et al. (2006). Regulation of cancer cell migration and bone metastasis by RANKL. Nature, 440, 692–696.PubMedCrossRef

70.

Shi, H. Y., Zhang, W., Liang, R., Kittrell, F., Templeton, N. S., Medina, D., et al. (2003). Modeling human breast cancer metastasis in mice: Maspin as a paradigm. Histology and Histopathology, 18, 201–206.PubMed

71.

Lockett, J., Yin, S., Li, X., Meng, Y., & Sheng, S. (2006). Tumor suppressive maspin and epithelial homeostasis. Journal of Cellular Biochemistry, 97, 651–660.PubMedCrossRef

72.

Gorden, D. L., Fingleton, B., Crawford, H. C., Jansen, D. E., Lepage, M., & Matrisian, L. M. (2007). Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment. International Journal of Cancer, 121, 495–500.CrossRef

73.

Lynch, C. C., Hikosaka, A., Acuff, H. B., Martin, M. D., Kawai, N., Singh, R. K., et al. (2005). MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell, 7, 485–496.PubMedCrossRef

74.

Lewis, C. E., & Pollard, J. W. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Research, 66, 605–612.PubMedCrossRef

75.

Leek, R. D., Hunt, N. C., Landers, R. J., Lewis, C. E., Royds, J. A., & Harris, A. L. (2000). Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. Journal of Pathology, 190, 430–436.PubMedCrossRef

76.

Wyckoff, J. B., Segall, J. E., & Condeelis, J. S. (2000). The collection of the motile population of cells from a living tumor. Cancer Research, 60, 5401–5404.PubMed

77.

Wang, W., Wyckoff, J. B., Goswami, S., Wang, Y., Sidani, M., Segall, J. E., et al. (2007). Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors. Cancer Research, 67, 3505–3511.PubMedCrossRef

78.

Condeelis, J., & Segall, J. E. (2003). Intravital imaging of cell movement in tumours. Nature Reviews. Cancer, 3, 921–930.PubMedCrossRef

79.

Luzzi, K. J., MacDonald, I. C., Schmidt, E. E., Kerkvliet, N., Morris, V. L., Chambers, A. F., et al. (1998). Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. American Journal of Pathology, 153, 865–873.PubMed

80.

Hiratsuka, S., Nakamura, K., Iwai, S., Murakami, M., Itoh, T., Kijima, H., et al. (2002). MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell, 2, 289–300.PubMedCrossRef

81.

Acuff, H. B., Carter, K. J., Fingleton, B., Gorden, D. L., & Matrisian, L. M. (2006). Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Research, 66, 259–266.PubMedCrossRef

82.

Hiratsuka, S., Watanabe, A., Aburatani, H., & Maru, Y. (2006). Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nature Cell Biology, 8, 1369–1375.PubMedCrossRef

83.

Lin, E. Y., & Pollard, J. W. (2004). Macrophages: Modulators of breast cancer progression. Novartis Foundation Symposium, 256, 158–168 discussion 68–72, 259–69.PubMed

84.

Kaplan, R. N., Psaila, B., & Lyden, D. (2006). Bone marrow cells in the ‘pre-metastatic niche’: Within bone and beyond. Cancer and Metastasis Reviews, 25, 521–529.PubMedCrossRef

85.

Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438, 820–827.PubMedCrossRef

86.

Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002). Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science, 295, 2387–2392.PubMedCrossRef

87.

Psaty, B. M., & Furberg, C. D. (2005). COX-2 inhibitors—Lessons in drug safety. New England Journal of Medicine, 352, 1133–1135.PubMedCrossRef

Titel: Immune cells as mediators of solid tumor metastasis
verfasst von: David G. DeNardo
Magnus Johansson
Lisa M. Coussens
Publikationsdatum: 01.03.2008
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2008
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-007-9100-0

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Immune cells as mediators of solid tumor metastasis

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Metastasis signatures: genes regulating tumor–microenvironment interactions predict metastatic behavior

Bio

Inflammation, inflammatory cells and angiogenesis: decisions and indecisions

The Met tyrosine kinase receptor in development and cancer

A “class action” against the microenvironment: do cancer cells cooperate in metastasis?

The bone microenvironment in metastasis; what is special about bone?

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie